This inventor holds 36 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 3 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Osmotica Kereskedelmi Es Szolgaltato Kft, Osmotica Kereskedelmi És Szolgáltató Korlátolt Felelösségû Társaság, Adamas Pharmaceuticals, Inc.. Active years: 2001-2024.
Location History:
- Wrightsville Beach, NC (US) (2001)
- Wilmington, DE (US) (2020)
- Wilmington, NC (US) (2001 - 2024)
Company Filing History:
20 out of 29 
5 out of 5 
2 out of 29 
Years Active: 2001-2024
Areas of Expertise:
Title: Glenn A Meyer: A Pioneer in Neurological Treatment Innovations
Introduction
Glenn A Meyer is an accomplished inventor based in Wilmington, North Carolina, renowned for his significant contributions to the field of neurological disease treatment. With an impressive portfolio of 36 patents, Meyer has made a substantial impact on medical science through his innovative approaches to challenging neurological disorders.
Latest Patents
Meyer’s latest patents focus on a composition and method for treating neurological diseases, specifically targeting conditions such as Parkinson's disease, drug-induced extrapyramidal reactions, and levodopa-induced dyskinesia. His method involves administering a pharmaceutical composition containing between 50 mg to 400 mg of extended-release amantadine or a pharmaceutically acceptable salt, highlighting a novel once-daily morning dosage that leverages the medication's therapeutic effects effectively.
Career Highlights
Throughout his career, Glenn A Meyer has collaborated with various companies to advance his research and innovations. He has notably worked at Osmotica Kereskedelmi Es Szolgaltato Kft, where he contributed to the development of groundbreaking treatments for neurological conditions.
Collaborations
Meyer has worked alongside notable professionals in the field, including Gustavo A Fischbein and Cristian R Franco. Their collaborative efforts have significantly enriched the research environment, fostering innovation and contributing to the development of new treatment methodologies for patients suffering from neurological disorders.
Conclusion
Glenn A Meyer stands out as a leading figure in the realm of neuropharmacology and treatment innovation. His extensive patents and dedicated work at Osmotica highlight his commitment to enhancing the quality of life for individuals affected by severe neurological conditions. As he continues to push the boundaries of medical science, Meyer's contributions will undoubtedly leave a lasting legacy in the field of healthcare.